Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Risk Factors for Inadequate Bowel Preparation Before Colonoscopy

NCT06878378 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2025-02-21
Last updated
2025-03-18

Condition(s) studied

ColonoscopyColonoscopy: Bowel Preparation

Investigational drug(s) / intervention(s)

Investigation of Factors Influencing Bowel Preparation Quality

Investigation of Factors Influencing Bowel Preparation Quality: Observed parameters include BMI, history of abdominal surgery, history of diabetes, history of diarrhea and constipation, stool characteristics, and specific bowel preparation protocols.

Study summary

The primary objectives of this study are twofold:

Firstly, to investigate the current status of bowel preparation protocols and their quality across hospitals at various levels in China, particularly following the release of the updated 2023 bowel preparation guidelines. This aims to standardize and optimize bowel preparation protocols nationwide.

Secondly, to identify and analyze risk factors contributing to suboptimal bowel preparation quality in patients undergoing colonoscopy. The study will examine the correlation between these factors and bowel preparation scores, establish a risk prediction model for preparation failure, and provide a theoretical foundation for developing personalized bowel preparation regimens tailored to individual patient characteristics.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Patients aged \>18 years, regardless of gender, scheduled for colonoscopy * Written informed consent has been obtained Exclusion Criteria: * History of acute myocardial infarction (within 6 months), severe cardiac/hepatic/renal insufficiency, or psychiatric disorders * Current use of anticoagulants (e.g., aspirin, warfarin) or presence of coagulation disorders * Pregnancy or lactation; * History of inflammatory bowel disease or acute intestinal infection within the past 2 weeks; * History of colorectal cancer, familial adenomatous polyposis (FAP), or Peutz-Jeghers syndrome; * History of intestinal obstruction, perforation, stricture, or other conditions precluding completion of colonoscopy; * Non-compliance with bowel preparation protocols (e.g., ingestion of \<80% of prescribed polyethylene glycol (PEG) electrolyte solution); * Severe hearing impairment, cognitive dysfunction, or inability to cooperate with the study; * Prior enrollment in this study with a repeat colonoscopy appointment; * Current participation in other clinical trials or participation in any trial within the preceding 60 days; * Refusal to provide written informed consent.

Primary outcome measure(s)

  • adequate bowel preparation rate — The adequate bowel preparation rate can be assessed immediately upon completion of colonoscopy

Trial sites (1)

FacilityCityRegionStatus
Changhai Hospital Shanghai Shanghai Municipality Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06878378 on ClinicalTrials.gov ↗ ← All trials in China